Latest News

Topas and Lilly sign deal to focus on immune tolerance

Topas and Lilly sign deal to focus on immune tolerance

Orchard’s OTL-101 receives promising medicine designation for ADA-SCID in UK

Biotechnology company Orchard Therapeutics’ OTL-101 has received a promising innovative medicine designation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the...

Orchard’s OTL-101 receives promising medicine designation for ADA-SCID in UK

AC Immune finds new antibodies targeting neurodegenerative diseases

Swiss clinical stage biopharmaceutical company AC Immune has discovered new antibodies against two targets, Alpha-synuclein and TDP-43, in the pathogenesis of neurodegenerative...

AC Immune finds new antibodies targeting neurodegenerative diseases

Takeda submits NDA for Vedolizumab to treat moderate-to-severe UC in Japan

Takeda submits NDA for Vedolizumab to treat moderate-to-severe UC in Japan

Sandoz’s Erelzi available for multiple inflammatory disease treatment in Canada

Novartis division Sandoz has made its Erelzi (etanercept) therapy available for the treatment of multiple inflammatory diseases for patients in...

Sandoz’s Erelzi available for multiple inflammatory disease treatment in Canada

MiMedx to divest Stability Biologics business to focus on biopharma

MiMedx Group has signed a new definitive agreement with former stockholders of Stability to sell its subsidiary, Stability Biologics, back to the stockholders to focus on...

MiMedx to divest Stability Biologics business to focus on biopharma

Champions Oncology to collaborate with ALCMI to develop new cohort of PDX models

Champions Oncology has entered into a collaboration deal with the Addario Lung Cancer Medical Institute (ALCMI) to develop a new cohort of PDX models in patients with ROS1 gene rearrangement. ...

Champions Oncology to collaborate with ALCMI to develop new cohort of PDX models

AstraZeneca, MedImmune and Ethris to develop mRNA treatments for respiratory diseases

AstraZeneca, along with its global biologics research and development unit MedImmune, and German biotech Ethris have entered a strategic research collaboration to develop stabilised...

AstraZeneca, MedImmune and Ethris to develop mRNA treatments for respiratory diseases

Pfizer’s Besponsa gets FDA approval for treatment of B-cell precursor ALL

Pfizer’s Besponsa gets FDA approval for treatment of B-cell precursor ALL

Cancer Research UK and Newcastle University extend drug discovery partnership with Astex

Cancer Research UK and Newcastle University extend drug discovery partnership with Astex

Deals this week: Kadmon Holdings, Antares Pharma, Vicarius Pharma

US-based biopharmaceutical company Kadmon Holdings (Kadmon) has announced a public offering of common stock shares to raise up to $40m in...

Deals this week: Kadmon Holdings, Antares Pharma, Vicarius Pharma

M&As this week: Guanhao Biotech, Cancer Genetics, Alvogen

Chinese biotechnology company Guanhao Biotech plans to acquire a 53.4% stake in two pharmaceutical companies based in China for CNY266m...

M&As this week: Guanhao Biotech, Cancer Genetics, Alvogen

SillaJen and NCI partner to develop new colorectal cancer treatment

SillaJen and NCI partner to develop new colorectal cancer treatment

Hikma and Takeda sign new licensing agreement to expand product portfolio in MENA

Hikma Pharmaceuticals has reached an agreement with Takeda Pharmaceutical Company to expand their licensing and distribution agreement to add new products to its existing portfolio in the...

Hikma and Takeda sign new licensing agreement to expand product portfolio in MENA

Shire submits marketing application for lifitegrast to treat dry eye disease in Europe

Shire submits marketing application for lifitegrast to treat dry eye disease in Europe

Evotec buys Aptuit for nearly $300m

German company Evotec has completed the acquisition of Aptuit for a total consideration of approximately $300m to support its long-term strategy to be the industry partner of choice for...

Evotec buys Aptuit for nearly $300m

Johnson & Johnson and CSIR-IMTECH partner to discover new tuberculosis treatments

Johnson & Johnson’s India-based business has signed a memorandum of understanding (MoU) with the Institute of Microbial Technology (IMTECH) to discover and develop new treatments for...

Johnson & Johnson and CSIR-IMTECH partner to discover new tuberculosis treatments

FDA grants orphan drug status to H3 Biomedicine’s cancer treatment H3B-8800

H3 Biomedicine, a member of Eisai’s global Oncology Business Group, has received orphan drug designation from the US Food and Drug Administration (FDA) for its H3B-8800, a clinical compound used...

FDA grants orphan drug status to H3 Biomedicine’s cancer treatment H3B-8800

Aradigm secures SBIR grant to investigate use of Linhaliq and Lipoquin for PNTM treatment

Aradigm has secured a small business initiative research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health...

Aradigm secures SBIR grant to investigate use of Linhaliq and Lipoquin for PNTM treatment

Amicus’ Galafold receives TGA approval for Fabry disease treatment in Australia

Amicus’ Galafold receives TGA approval for Fabry disease treatment in Australia

Three quarters of CDF treatments now approved on NHS

Three quarters of CDF treatments now approved on NHS
cachename:Newscachekey:rd-1665407042_1857678299_rd-488908060_1460672566_rd1460672566_371857150_ap1460672566_1857678299_946450448